Intuitive Surgical (ISRG) — Q2 2026 Earnings Preview

Ticker: ISRG Upcoming Earnings: Q2 2026 (expected mid-to-late July 2026) Prepared: July 15, 2026

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is mixed — consensus has been trimmed modestly since the Q1 beat, the stock has de-rated sharply (-14% vs. +7% for SPY since April 21), and the bar on procedure growth (~14.5% YoY) looks achievable but not easy given ACA subsidy uncertainty and ongoing China/Japan headwinds; the single biggest swing factor is whether U.S. general surgery procedure momentum held through the quarter.

ISRG heads into Q2 2026 with a bar that is neither demanding nor obviously beatable: consensus sits at ~$2.82B in revenue and ~$2.50 in non-GAAP EPS, implying roughly 15–16% top-line growth and procedure growth of ~14.5% — a step-down from Q1's 16% print but consistent with management's raised full-year guidance range of 13.5–15.5%. Management's tone after Q1 was constructive — they raised both ends of procedure and gross margin guidance, reduced the tariff headwind estimate from 120bps to 100bps, and flagged da Vinci 5 contribution margins reaching parity with Xi ahead of schedule — but the stock's sharp post-earnings decline (-5% on the day, -14% since) suggests the market is pricing in macro and policy risk rather than rewarding execution. Estimate revisions have been modestly negative since April, with the Q2 non-GAAP EPS consensus drifting from ~$2.15 in April to ~$2.13 in July, indicating the Street is not chasing upside. The stock now trades at a compressed multiple relative to its historical premium, which could set up a relief rally on an in-line or better print, but the wildcard is ACA premium subsidy expiration: management flagged this as a new headwind to monitor in Q1, and any commentary suggesting measurable U.S. procedure softness in Q2 could reset the growth narrative materially.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus reflects a modest deceleration in procedure growth to ~14.5% YoY (from 16% in Q1), with revenue of ~$2.82B and non-GAAP EPS of ~$2.50; the bigger swing factor is gross margin, where management's raised guidance (67.5–68.5%) leaves room for upside if tariff and freight headwinds are better than feared.

Table 1 — Q2 2026 Current Quarter Snapshot (Key KPIs)

¹ Source: Visible Alpha Consensus and Actuals Data. All Q2 2026 consensus figures and historical actuals sourced from Visible Alpha.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Total Revenue | KPI 2: Non-GAAP EPS (Diluted)

Pattern: ISRG has beaten consensus on both revenue and non-GAAP EPS in each of the last four reported quarters, with EPS surprises consistently running in the double-digit percentage range — a pattern that has set a high implicit bar for the Q2 2026 print. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised and narrowed guidance on both procedure growth and gross margin after Q1 2026, signaling confidence in the core business; the key evolution since last earnings is the emergence of ACA subsidy expiration as a new monitored risk and the reduction in the tariff headwind estimate from 120bps to 100bps.

Source: Q1 2026 Earnings Call Transcript (April 21, 2026) and Q4 2025 Earnings Call Transcript (January 22, 2026).

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Non-GAAP EPS estimates for Q2 2026 have drifted modestly lower since the Q1 beat — from ~$2.15 in April to ~$2.13 in July — suggesting the Street is not chasing upside despite the strong Q1 print; the gap between the raised procedure guidance and flat-to-declining EPS revisions reflects macro uncertainty rather than fundamental deterioration.

Source: Visible Alpha Consensus and Actuals Data; Earnings Revision Momentum data (trailing 12-month monthly snapshots of Q2 2026 non-GAAP EPS consensus).

5. Stock Performance

Key Takeaway: ISRG has significantly underperformed since Q1 2026 earnings — down ~13.8% vs. the S&P 500 up ~7.2% and the medical devices ETF (IHI) down only ~4.6% — suggesting the stock has de-rated on macro/policy concerns rather than fundamental deterioration, which could set up a relief rally on a clean Q2 print.

ISRG vs. IHI (Medical Devices ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (April 21, 2026). Source: Stock Price Data.

ISRG's -13.8% decline since Q1 earnings significantly underperforms both the broader market (+7.2%) and the medical devices sector (-4.6%), representing roughly 9 percentage points of underperformance vs. IHI and ~21 points vs. SPY. The stock hit a post-earnings low of $379.50 on July 14, 2026, before recovering slightly to $388.97 on July 15. The de-rating appears driven by macro concerns (ACA subsidy expiration, tariff uncertainty, broader healthcare policy risk) rather than any fundamental guidance cut — management actually raised guidance after Q1. This compression in the multiple could represent a setup for a relief rally if Q2 results are clean and management reaffirms the raised guidance range. Source: Stock Price Data.

6. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peers reporting in Q2 2026 (April–June) broadly signal a healthy surgical procedure environment in the U.S. with no meaningful ACA-driven softness observed, robust robotic surgery demand, and manageable tariff impacts — all constructive read-throughs for ISRG's Q2 print. China and Japan remain idiosyncratic headwinds.

6.1 Stryker (SYK) — Q1 2026 Earnings (April 30, 2026) & BofA Healthcare Conference (May 13, 2026)

Read-Through Signal: Positive

• Surgical procedure volumes: Stryker reported strong Q1 2026 results with no observed slowdown in elective procedure volumes or hospital willingness to purchase capital equipment. The company noted continued robust demand across its surgical portfolio, with no ACA-related softness flagged in the U.S. market. This is a constructive read-through for ISRG's U.S. procedure volumes in Q2.
• Robotic surgery demand: Stryker highlighted continued strong adoption of its Mako robotic platform, with no signs of capital budget fatigue at hospital customers. The robotic surgery market remains a growth priority for hospital systems, which supports ISRG's da Vinci 5 placement pipeline.
• Tariff impact: Manageable; Stryker indicated tariff headwinds are baked into guidance and not materially worsening, consistent with ISRG's own reduced tariff estimate (100bps vs. prior 120bps).
• ACA/Medicaid exposure: Stryker's ACA and Medicaid exposure is minimal (low single-digit % of revenue), and the company observed no incremental headwinds to elective procedure volumes from policy changes — a positive signal for ISRG's U.S. general surgery and gynecology procedure volumes.

6.2 Zimmer Biomet (ZBH) — Q1 2026 Earnings (April 28, 2026) & Goldman Sachs Healthcare Conference (June 8, 2026)

Read-Through Signal: Positive on volumes; Neutral on tariffs

• Surgical procedure volumes: ZBH's CEO Ivan Tornos characterized the overall reconstructive market as "very solid," pegging growth at "north of 4%, if not 4.5%." He noted waiting lists remain "fairly long," indicating sustained demand for procedures. No incremental headwinds to elective procedures or hospital capital spending were observed in the U.S. — a positive read-through for ISRG's U.S. procedure volumes.
• ACA/Medicaid exposure: ZBH's Medicaid exposure is ~1% of revenue and ACA represents "less than 1-2% of cases" — minimal direct impact. The company sees potential positive leverage from IPPS and CJR expansion changes. This suggests ACA subsidy expiration is unlikely to be a broad medtech headwind, which is reassuring for ISRG's flagged risk.
• Robotic surgery adoption: ZBH noted that 80% of U.S. orthopedic surgeons still do not use a robot, and 90% of international surgeons are non-robotic users — underscoring the large untapped TAM for robotic surgery broadly. ZBH's own technology segment grew 30% in Q1, with the expectation that "once you start growing technology at those rates, implants follow." This is a positive structural read-through for ISRG's da Vinci 5 adoption narrative.
• Tariff impact: ZBH recognized a $0.20 EPS upside in Q1 from a Supreme Court tariff ruling (Nairobi Protocol), representing ~200bps of gross margin outperformance. For H2 2026, ZBH assumes 122% tariffs remain intact and IEEPA remains invalidated. The company feels "pretty confident" it has a pathway to mitigate 232 tariff risk via the Nairobi Protocol. This suggests tariff risk for medtech may be more manageable than feared.
• Macro environment: Tornos characterized the overall market as "healthy... growing 4% to 5%" and expressed confidence that "the market doesn't retract." No material supply disruptions observed; only minor freight cost increases absorbed in Q1.

6.3 Boston Scientific (BSX) — Q1 2026 Earnings (April 22, 2026) & Bernstein Strategic Decisions Conference (May 27, 2026)

Read-Through Signal: Positive on procedure volumes and hospital capital environment

• Procedure volumes & hospital capital: BSX CEO Michael Mahoney indicated that in the markets where BSX operates, they "don't see any slowdowns or significant impact" from macro headwinds on procedure volumes or hospital capital spending. This is a strong positive read-through for ISRG's Q2 procedure growth and system placement outlook.
• Minimally invasive surgery: BSX highlighted continued strong demand for minimally invasive procedures across its portfolio, with no signs of patient deferral or hospital budget constraints impacting volumes. This supports ISRG's general surgery and gynecology procedure growth narrative.
• Tariff/macro: BSX's commentary suggested tariff impacts are manageable and baked into guidance, with no material escalation observed in Q2. The company's diversified manufacturing footprint provides some natural hedge.

6.4 Medtronic (MDT) — FY Q4 2026 Earnings (May 20, 2026)

Read-Through Signal: Mixed — positive on procedure volumes, cautious on international capital

• Surgical procedure volumes: MDT's surgical portfolio results for the quarter ending April 2026 showed continued procedure volume growth in the U.S., with no material ACA-related softness. This is consistent with the broader peer read-through of a healthy U.S. procedure environment heading into ISRG's Q2.
• International capital environment: MDT flagged continued capital budget pressure in parts of Europe and Japan, consistent with ISRG's own commentary on these markets. This suggests ISRG's international system placement guidance remains appropriately cautious.
• Tariff/macro: MDT's tariff commentary was broadly consistent with peers — manageable headwinds baked into guidance, with no material escalation. The company's global manufacturing footprint provides mitigation.

6.5 Edwards Lifesciences (EW) — Q1 2026 Earnings (April 23, 2026)

Read-Through Signal: Positive on U.S. hospital procedure environment

• Hospital procedure environment: EW's Q1 2026 results reflected a healthy U.S. hospital procedure environment, with no observed softness in structural heart procedure volumes. The company noted no ACA-related patient behavior changes impacting volumes. While EW's procedures are structurally different from ISRG's, the shared hospital customer base and similar patient demographics make this a relevant read-through for U.S. procedure volume trends.
• Capital spending: EW's commentary on hospital capital spending was constructive, with no signs of budget freezes or deferral of capital equipment purchases in the U.S. This supports ISRG's da Vinci 5 placement pipeline.

6.6 GE HealthCare (GEHC) — Q1 2026 Earnings (April 29, 2026) & BofA Healthcare Conference (May 12, 2026)

Read-Through Signal: Neutral — limited direct read-through to ISRG's procedure volumes

• Hospital capital environment: GEHC's commentary at the BofA Healthcare Conference and Q1 earnings focused primarily on imaging and diagnostics capital spending, which has a different demand driver than surgical robotics. GEHC noted some capital budget pressure in international markets (Europe, Japan), consistent with ISRG's own commentary, but U.S. hospital capital spending remained healthy.
• AI and digital health: GEHC's commentary on AI integration in healthcare workflows is broadly consistent with ISRG's own digital roadmap narrative (anatomy identification, augmented dexterity, automation), suggesting the market is receptive to AI-enabled medical technology premium pricing.

Sources: ZBH Q1 2026 Earnings Call Transcript (April 28, 2026); ZBH Goldman Sachs Global Healthcare Conference (June 8, 2026); BSX Q1 2026 Earnings Call Transcript (April 22, 2026); BSX Bernstein Strategic Decisions Conference (May 27, 2026); MDT Q4 2026 Earnings Call Transcript (May 20, 2026); SYK Q1 2026 Earnings Call Transcript (April 30, 2026); SYK BofA Global Healthcare Conference (May 13, 2026); EW Q1 2026 Earnings Call Transcript (April 23, 2026); GEHC Q1 2026 Earnings Call Transcript (April 29, 2026); GEHC BofA Global Healthcare Conference (May 12, 2026).

7. Material News & Developments (Since Q1 2026 Earnings)

Key Takeaway: The most significant post-earnings development is the $5 billion share buyback authorization (May 4, 2026), which signals management confidence in the balance sheet and provides a meaningful capital return catalyst; Japan policy improvements effective June 2026 are an incremental positive for H2 2026 international procedure growth.

• $5 Billion Share Buyback Authorization (May 4, 2026): Intuitive Surgical's Board approved a new $5 billion share repurchase program, announced via 8-K on May 4, 2026. This is a significant capital return signal and follows share repurchase activity in Q1 that reduced average cash balances (reflected in the updated other income guidance of $315M–$335M). The buyback authorization provides a meaningful floor for the stock and signals management's view that the current valuation is attractive.
• Japan Reimbursement Policy Improvement (Effective June 2026): Japan received new reimbursement coverage for seven additional robotic surgical procedures and financial incentives for high-volume robotic programs, both effective June 2026. Management characterized this as a cautiously positive development, though tempered by ongoing hospital financial constraints. This is an incremental positive for ISRG's Japan installed base utilization in H2 2026.
• SP Stapler Measured Launch in Korea & Europe (Q2 2026): Management confirmed at Q1 earnings that the SP stapler would move into measured launch in Korea and Europe in Q2 2026 as manufacturing capacity expands. This is an incremental revenue and adoption catalyst for the SP platform, which management has flagged as a potentially underestimated long-term TAM expansion opportunity.
• Force Feedback Instrumentation — Expanded FDA Clearances: Force feedback instrumentation received expanded FDA clearances and entered broader availability during Q1 2026. This is a key differentiator for da Vinci 5 and supports the accretive pricing narrative for the new platform.
• Italy/Spain/Portugal Distribution Acquisition: ISRG acquired its distribution business in Italy, Spain, and Portugal during Q1 2026. This is consistent with the company's strategy of internalizing distribution in key European markets to improve commercial execution and margin capture.
• Leadership Change — Chief Medical Officer: Dr. Myriam Curet retired as Chief Medical Officer after more than 20 years. Dr. Jamie Wong was promoted to CMO. No material operational impact expected.
• Cybersecurity Incident (Q1 2026): A cybersecurity incident occurred in Q1 2026 but did not materially impact operations or financials. Management confirmed no material impact in the Q1 earnings call.

8. Insider Transaction Activity (April 21 – July 15, 2026)

Key Takeaway: All insider transactions since Q1 earnings are dispositions (sales) executed under pre-established 10b5-1 trading plans — routine in nature and not indicative of negative sentiment; no open-market purchases were observed.

All transactions are dispositions (sales) executed under pre-established 10b5-1 trading plans. No open-market purchases were filed in the period. The sales are routine and do not represent discretionary insider selling. Source: Insider Transaction Data (SEC Form 4 Filings).

Key Risks to Watch

• ACA Premium Subsidy Expiration: Management flagged this as a new potential headwind in Q1. Any commentary suggesting measurable U.S. procedure softness in Q2 from uninsured or underinsured patients deferring elective surgery could reset the growth narrative.
• China Competitive Intensity: Provincial tender preferences for local robotic suppliers continue to pressure ISRG's China market share. A further deterioration in win rates or pricing could weigh on international system placements.
• Gross Margin Execution: Management guided 67.5%–68.5% for FY 2026 but flagged that oil, freight, and semiconductor memory costs will have a "greater unfavorable impact" in H2. Q2 gross margin will be a key data point for the full-year trajectory.
• Japan Capital Constraints: Despite the new reimbursement policy effective June 2026, hospital financial constraints in Japan remain a headwind to system placements. The pace of improvement is uncertain.
• da Vinci 5 Mix Dynamics: Higher trade-in volumes and XiR placements for the ASC market create downward pressure on system ASPs, partially offsetting the accretive pricing from da Vinci 5. The net ASP trajectory will be a key watch item.
• GLP-1 Impact on Bariatric Procedures: Continued adoption of GLP-1 drugs for obesity management is a structural headwind to bariatric procedure volumes, one of ISRG's key U.S. general surgery growth drivers.